Assessing improvement area policy

The Inner Cities Directorate of the DoE have commissioned a number of studies to examine and evaluate the impact of economic and environmental measures adopted under the Urban Programme. This paper examines one such study, namely an evaluation of designated Industrial and Commercial Improvement Areas. It comments on the criteria of assessment adopted, the methodology used and the conclusions drawn from the evaluation. The study in question is An Evaluation of Industrial and Commercial Improvement Areas, by the Joint Unit for Research on the Urban Environment (JURUE), published in 1984.     

Using social media to report financial results

The growing influence of social media on financial performance reporting creates opportunities and challenges for both executives and corporate communications teams. This Accounting Matters feature provides background on current business reporting practices (including new SEC regulations) and insights from recent research on communication of financial results. The conclusion discusses future trends and provides recommendations for executives to consider when designing, implementing, and evaluating media and investor relations communication initiatives.     

Economics and the treatment of AIDS: a preliminary assessment

This paper applied cost-effectiveness analysis to the use of drug therapy in the treatment of AIDS. The empirical approach adopted overcame the facts that the samples of patients had varying clinical prognoses, had variable entry dates into the samples and, because AIDS is a terminal disease, had variable exit dates. Holding these variables constant, administration of the drug AZT proved to be a less costly alternative than other existing palliatives for AIDS. The sub-sample of patients treated with AZT had lower hospitalization costs, lower caring costs and sufferers had an increased ability to continue to participate for longer as economically active members of society.     

Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States

Background: Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FVIII (rFVIII), demonstrated higher inhibitor rates in previously untreated patients (PUPs) treated with rFVIII than in PUPs treated with pdFVIII/VWF.

Objective: To quantify the economic impact of treating PUPs with pdFVIII/VWF vs rFVIII.

Methods: An Excel-based clinical and economic model was developed from a US healthcare payer perspective and run over a 5-year period. The analysis utilized a cohort approach to model patient treatment and outcomes over a monthly cycle to quantify differences in costs of FVIII, bypassing agents, and hospitalizations for serious bleeds. Rates of high-titer inhibitor development were obtained from the SIPPET study. Patients developing high-titer inhibitors were treated with immune tolerance induction (ITI). Patients who developed low-titer inhibitors and those who did not develop inhibitors continued their usual FVIII treatment. Patients who were successfully treated with ITI returned to FVIII treatment, while unsuccessfully treated patients received bypassing agents. Total costs per treated patient were estimated and a one-way sensitivity analysis was conducted to quantify the impact of parameter uncertainty on the model outcomes.

Results: Total cumulative costs per patient over 5 years were $834,621 for pdFVIII/VWF patients and $1,237,163 for rFVIII patients, representing a total saving of $402,542 per patient over the 5-year period, for an average annual saving of $80,508 per patient.

Conclusions: Based on data from the SIPPET study, this analysis found that initiating FVIII treatment in severe hemophilia A PUPs with pdFVIII/VWF has the potential to offer substantial cost savings to healthcare payers, amounting to a one-third reduction in costs.     

Warum und wie die Liberalisierung des Cannabismarktes in Deutschland erfolgen sollte

Wirtschaftsdienst - Der vorliegende Beitrag fasst die Argumente für eine Legalisierung von Cannabis zusammen und macht Vorschläge zur Ausgestaltung des Regulierungsrahmens. Hauptargument...     

Debt Relief as a Last Resort for the Lender of Last Resort?

The coronavirus crisis has led to a sharp increase in the debt-to-GDP ratios of the euro area member states. Without external support, access to the capital market could be seriously threatened in the medium term for Italy, but also for other member states. While the Pandemic Emergency Purchase Programme, which is designed as a monetary policy instrument, is regarded by some as a violation of the prohibition of monetary financing, the Next Generation EU recovery fund is likely to direct the fundamental structures of the European Union towards a fiscal union with considerable redistribution elements. This article analyses an alternative strategy, namely debt relief by the European System of Central Banks through an EU debt agency. Such a scheme would be possible without amending the EU treaties and would avoid negative equity at the central banks. The question is under what circumstances would this approach be suitable and proportionate?

     

Innovation Offshoring,Institutional Context and Innovation Performance: A Meta‐Analysis

Innovation offshoring (IO) has become a widespread management practice. Yet, evidence on the performance implications is inconsistent, and scattered across disciplines and contexts. We argue that the benefits firms can derive from IO depend on the institutional environment at home. Drawing on recent work on institutional theory in international business, we explore institutions that facilitate reverse knowledge transfer and/or institutional arbitrage with respect to innovation‐related activities. The results of our meta‐analysis that synthesizes evidence from 48 samples show that IO is related positively to innovation performance. As predicted, this relationship is moderated by differences in the institutional environments across countries. Specifically, when national innovation systems are weak at home, IO appears to enable institutional arbitrage strategy whereas Confucian cultures enable more effective reverse knowledge transfer. However, contrary to our expectations, the beneficial effects of IO appear to have diminished over time.